ALHYG Stock Overview
Hybrigenics SA, together with its subsidiaries, operates as a biotechnology company in France.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Hybrigenics SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.012 |
| 52 Week High | €0.07 |
| 52 Week Low | €0.011 |
| Beta | 0 |
| 1 Month Change | -6.35% |
| 3 Month Change | -33.71% |
| 1 Year Change | -81.39% |
| 3 Year Change | -95.59% |
| 5 Year Change | n/a |
| Change since IPO | -89.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALHYG | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -2.5% | -0.1% | -0.2% |
| 1Y | -81.4% | -10.2% | 2.3% |
Return vs Industry: ALHYG underperformed the French Biotechs industry which returned -10.2% over the past year.
Return vs Market: ALHYG underperformed the French Market which returned 2.3% over the past year.
Price Volatility
| ALHYG volatility | |
|---|---|
| ALHYG Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.8% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALHYG's share price has been volatile over the past 3 months.
Volatility Over Time: ALHYG's weekly volatility has decreased from 16% to 7% over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.hybrigenics.com |
Hybrigenics SA, together with its subsidiaries, operates as a biotechnology company in France. The company engages in development of biotechnology in the field of biotechnology, oncology, regenerative medicine, and anti-aging medicine. It is also involved in the development of technical solutions using adipose tissue cells and stem cells.
Hybrigenics SA Fundamentals Summary
| ALHYG fundamental statistics | |
|---|---|
| Market cap | €4.52m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs ALHYG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALHYG income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ALHYG perform over the long term?
See historical performance and comparison